Candesartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C24H20N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8Q36MD2XX, chemically known as 1h-benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)- but generally known as candesartan, which bears US NIH Compound Identifier 2541. Candesartan most often comes in base, celexetil, and hexetil forms. European Medicines Agency schedules Candesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06070MIG. The term CANDESARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules candesartan in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule candesartan under HS 29339990 and SITC 51577. As of Q4 2014, CANDESARTAN remains the US FDA Preferred Term for this commodity. Candesartan bears US NLM identifiers UMLS ID C0717550 and NCI Concept Code C65284. SMILES: O(c1n(Cc2ccc(cc2)c2c(cccc2)c2n[nH]nn2)c2c(n1)cccc2C(=O)O)CC.